Table 16.8 Melanoma of the Skin (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival	(Percent)								
Year of Diagnosis:	(I CI CCIIC)								
1960-1963 ^a	-	_	_	60	51	68	_	_	_
1970-1973 ^a		_	_	68	62	75	_	_	_
1975-1977 ^b	81.9	77.5	86.3	82.0	77.7	86.2	56.7 ^g		_
1978–1980 ^b	82.8	77.7	87.7	82.9	77.9	87.9	59.8 ^h	_	_
1981–1983 ^b	82.8 82.8						59.8 61.9 ^g	_	
		78.4	87.3	82.7	78.4	87.2			-
1984-1986 ^b	86.6	82.6	91.0	86.4	82.2	91.0	72.3 ^h	-	
1987-1989 ^b	88.1	84.9	91.5	87.9	84.9	91.3	78.6 ^g	-	89.5
1990-1992 ^b	89.2	87.0	91.8	89.3	87.1	91.8	59.6 ^g	-	-
1993-1995 ^b	89.7	87.3	92.6	89.6	87.1	92.6	69.5 ^g	66.6 ^g	-
1996-1998 ^b	91.0	89.5	92.7	90.9	89.3	92.7	73.9 ^g	68.0 ^h	78.6
1999-2001 ^b	92.2	90.1	94.6	92.2	90.2	94.6	73.2 ^g	69.6 ^g	76.1
2002-2006 ^b	93.1	91.3	95.2	93.2	91.4	95.4	72.9 ^g	70.0 ^g	74.5
2007-2013 ^b	93.6 ^f	92.0 ^f	95.7 ^f	93.6 ^f	91.9 ^f	95.7 ^f	69.0 ^g	59.5 ^g	74.9
5-Year Period Survival ()	Percent) ^{cd}								
2013	91.8	89.9	94.2	91.3	89.2	93.9	56.8	48.4	61.6
Stage Distribution (%) 2 All Stages	007-2013 ^{ce}								
Number of cases	99,169	55,971	43,198	92,350	52,435	39,915	464	199	265
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	84	82	86	83	81	86	53	45	60
Regional	9	10	7	9	10	8	26	32	21
Distant	4	5	3	4	5	3	16	16	15
Unstaged	3	3	4	3	3	3	5	8	3
5-Year Relative Survival	(Percent), 2	007-2013 ^c							
Age at Diagnosis:							50 5 ⁰	co ob	
Ages <45	94.4	90.8	96.8	94.2	90.4	96.7	78.7 ^g	68.2 ^h	84.4
Ages 45-54	92.9	90.5	95.6	92.6	89.9	95.5	65.0 ^g	61.6 ^g	68.4
Ages 55-64	91.5	89.8	94.2	91.0	89.2	93.9	65.7 ^g	56.3 ^g	75.2
Ages 65-74	91.9	90.6	94.3	91.5	90.1	94.1	60.5 ⁹	58.2 ^h	61.3
Ages 75+	86.7	86.4	87.2	85.8	85.4	86.4	50.0 ^g	32.6 ^h	55.6
Ages <65	92.8	90.2	95.7	92.5	89.7	95.5	69.8	61.7 ^g	76.4
Ages 65+	89.6	88.8	90.8	88.9	88.1	90.4	55.9 ^g	49.0 ^g	59.0
Stage ^e :									
All Stages	91.7	89.7	94.2	91.2	89.1	94.0	64.6	57.9	68.7
Localized	98.5	97.9	99.2	98.1	97.4	99.0	86.4	90.3 ^g	83.5
Regional	62.9	97.9 60.1	99.2 67.7	63.2	97.4 60.4	68.0	46.4 ^g	37.2 ^g	54.6
	19.9	18.3	23.5	63.2 19.8	18.3	23.0	46.4 ³ 20.0 ^g	37.2° 10.7 ^g	54.0 30.1
Distant		18.3 80.4		19.8	18.3 79.1	23.0 84.8	20.03	10.75	30.1
Unstaged	82.6		85.3						

Based on End Results data from a series of hospital registries and one population-based registry.

SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Based on follow-up of patients into 2014.

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2014.

Period survival provides a 2013 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival),

(2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival). Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding. The difference between 1975-1977 and 2007-2013 is statistically significant (p<.05).

The standard error is between 5 and 10 percentage points.

The standard error is greater than 10 percentage points.

Statistic could not be calculated due to fewer than 25 cases during the time period.

b

С

d

e

f

g

h

_